


# Synthesis of Benzo[*a*]carbazoles and an Indolo[2,3-*a*]carbazole from 3-Aryltetramic Acids

Nathanyal J. Truax, Fernando Banales Mejia, Deborah O. Kwansare, Megan M. Lafferty, Maeve H. Kean, and Erin T. Pelkey\*

Department of Chemistry, Hobart and William Smith Colleges, Geneva, New York 14456, United States

**S** Supporting Information

**ABSTRACT:** A simple and flexible approach to 3-pyrrolin-2-one fused carbazoles is disclosed. The key step involves the  $\text{BF}_3$ -mediated electrophilic substitution of indoles with *N*-alkyl-substituted 3-aryltetramic acids, which provides access to indole-substituted 3-pyrrolin-2-ones. Scholl-type oxidative cyclizations of these materials led to the formation of the corresponding 3-pyrrolin-2-one-fused benzo[*a*]carbazoles and indolo[2,3-*a*]carbazoles. This work represents the first synthesis of the benzo[*a*]pyrrolo[3,4-*c*]carbazol-3(8*H*)-one ring system, while the indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazol-5-one ring system is found in a number of biologically active compounds including the protein kinase C (PKC) inhibitor, staurosporine.



This work represents the first synthesis of the benzo[*a*]pyrrolo[3,4-*c*]carbazol-3(8*H*)-one ring system, while the indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazol-5-one ring system is found in a number of biologically active compounds including the protein kinase C (PKC) inhibitor, staurosporine.

Indolo[2,3-*a*]carbazoles comprise an important class of biologically active heterocycles (Figure 1).<sup>1,2</sup> For example,




Figure 1. Structures of fused carbazole ring systems.


staurosporine (**1**)<sup>3</sup> is a potent inhibitor of protein kinase C (PKC).<sup>4</sup> Hudkins and co-workers investigated structure–activity relationships by preparing carbocyclic<sup>5</sup> and heterocyclic<sup>6</sup> fused variants of the indolo[2,3-*a*]carbazole ring system. One of these analogs, an indazolo[5,4-*a*]carbazole named CEP-11981 (**2**), was found to be a vascular endothelial growth factor (VEGF) inhibitor<sup>7</sup> and advanced to Phase I clinical trials.<sup>8</sup> Interestingly, the parent benzo[*a*]carbazole **3** has not previously been reported.<sup>9,10</sup>

We are interested in developing synthetic strategies that can be used to prepare indolo[2,3-*a*]carbazoles and new heterocyclic analogs such as **3**. Toward this end, we have explored the use of tetramic acid derivatives to prepare 3,4-diaryl-3-pyrrolin-2-ones (**4**) (Scheme 1).<sup>11–13</sup> Palladium-catalyzed cross-coupling reactions of tetramic acid triflates with arylboronic acids give **4**. Rather than using costly indolylboronic acids to prepare indole-substituted 3-pyrrolin-2-ones **5**, we became interested in developing a new strategy that takes advantage of the inherent reactivity of the electron-rich indole ring system.<sup>14</sup> We were inspired by a report by Prabhakar and co-workers;<sup>15</sup>

## Scheme 1. Arylation Reactions of Tetramic Acids


### Previous Work (Ref 11)

Cross-coupling of tetramic acid triflates



### This Work

Direct arylation of tetramic acids




they found that treatment of *N*-benzoyltetramic acid with 2,2'-biindole in the presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  gave a biindole-substituted 3-pyrrolin-2-one with loss of the benzoyl group. To preclude the possibility of *N*-deprotection, we decided to systematically study the synthesis of **5** using *N*-alkyltetramic acids. Realization of this strategy would offer significant advantages over the cross-coupling strategy as it does not require functionalization of the enolic moiety into a triflate nor does it require the use of palladium catalysts or arylboronic acids.

The requisite *N*-alkyl-3-aryltetramic acids **8** were prepared using the one-pot tandem amidation-Dieckmann cyclization reported by Le Gall and co-workers (Scheme 2).<sup>16,17</sup> The

Received: May 7, 2016


Published: July 8, 2016

## Scheme 2. Synthesis of 3-Aryltetramic Acids



cyclocondensation of ethyl *N*-alkylglycinate **6**<sup>18</sup> and arylacetates **7**<sup>19</sup> by treatment with *t*-BuOK gave tetramic acids **8** in mostly good yields. The latter were conveniently isolated as crystalline materials directly from the workup of these reactions. We chose to make *N*-*tert*-butyl tetramic acid **8f** in order to explore the possibility of making the free *N*-H lactams later by removal of the *tert*-butyl groups.<sup>20</sup> Interestingly, this tandem reaction failed to give indole-substituted tetramic acid **8g**.

We next explored Lewis-acid mediated arylation reactions using *N*-propyltetramic acid **8c** as the electrophilic partner and *N*-methylindole (**9a**) as the nucleophilic partner (Table 1, entry

Table 1. Screening Reaction Conditions<sup>a</sup>

entry	Lewis acid	solvent	temp (°C)	time (h)	conversion <sup>b</sup>
1	BF <sub>3</sub> ·Et <sub>2</sub> O	CH <sub>2</sub> Cl <sub>2</sub>	40	20	13 <sup>c</sup>
2	BF <sub>3</sub> ·Et <sub>2</sub> O	THF	65	1	0
3	BF <sub>3</sub> ·Et <sub>2</sub> O	CH <sub>3</sub> CN	65	1	0
4	BF <sub>3</sub> ·Et <sub>2</sub> O	DCE	65	1	7
5	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	65	1	25
6	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	65	4	40
7	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	65	24	54
8	BF <sub>3</sub> ·Et <sub>2</sub> O	PhMe	65	1	37
9	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	100	0.25	53
10	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	100	0.5	70
11	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	100	0.75	65
12	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	100	1	64
13	BF <sub>3</sub> ·Et <sub>2</sub> O	PhCl	100	4	45
14	BF <sub>3</sub> ·Et <sub>2</sub> O	PhMe	100	1	80
15	AlCl <sub>3</sub>	PhCl	100	0.5	0
16	FeCl <sub>3</sub>	PhCl	100	0.5	<i>d</i>
17	InCl <sub>3</sub>	PhCl	100	0.5	27
18	Cu(OTf) <sub>2</sub>	PhCl	100	0.5	<i>d</i>


<sup>a</sup>0.40 mmol of **8c**, 0.48 mmol of *N*-methylindole (**9a**), and 0.60 mmol of Lewis acid used. <sup>b</sup>Estimated by using ratio of ring methylene signals (<sup>1</sup>H NMR) of **5c** and **8c** averaged from at least two trials. <sup>c</sup>Using a 2.0 mmol scale, 11% isolated yield of **5c** was obtained. <sup>d</sup>NMR showed neither **8c** nor **5c**.

1). Following similar reaction conditions to that reported by Prabhakar,<sup>15</sup> we treated **8c** and **9a** with BF<sub>3</sub>·Et<sub>2</sub>O in CH<sub>2</sub>Cl<sub>2</sub> and 3 Å molecular sieves at rt for 20 h and obtained an 11% yield of indole product **5c**.

To improve the yield of **5c**, we screened different reaction conditions (Table 1). The reactions were analyzed by evaluating the crude <sup>1</sup>H NMR spectra and determining the ratio of product **5c** to starting material **8c** based on the relative respective methylene protons ( $\delta$ 3.90 for **8c** and  $\delta$ 4.45 for **5c**). The best conditions obtained included PhMe, 100 °C, and a reaction time of 1 h (Table 1, entry 14). Longer reaction times gave lower relative amounts of product (Table 1, entry 12 vs entry 13) and this result was rationalized by control experiments, which indicated that the product was being degraded over time.<sup>21</sup> We tried a few alternate Lewis acids (AlCl<sub>3</sub>, FeCl<sub>3</sub>, InCl<sub>3</sub>, Cu(OTf)<sub>2</sub>) to mediate the transformation, but we did not find a better Lewis acid than BF<sub>3</sub>·Et<sub>2</sub>O.

Using the best conditions from our screen, we next explored substrate scope (Scheme 3). We quickly found that PhMe was

## Scheme 3. Substrate Scope




not suitable for larger scale reactions (perhaps due to solubility issues), so we used PhCl as the solvent moving forward (Table 1, entry 10). Treatment of indoles **9** with tetramic acids **8** gave 3,4-diaryl-3-pyrrolin-2-ones **5**. The indolylation reaction worked well with *N*-methylindole **9a**; on the other hand, a much lower yield was obtained with parent indole (**9b**) during the preparation of *N*-unsubstituted indole **5h**.

We also tried *N*-(phenylsulfonyl)indole **9c**<sup>22</sup> (R = SO<sub>2</sub>Ph) in the indolylation reaction and we did not observe any arylation product **5i** (Scheme 3); this result illustrates that electron-withdrawing groups on indole inhibit the reaction.

A possible mechanism for this transformation is proposed (Scheme 4). Association of BF<sub>3</sub> with the lactam carbonyl promotes the condensation reaction between the tetramic acid and the indole. Loss of water and disassociation of the Lewis acid gives the product. Similar reactions involving indoles and cyclic ketones have been reported by others leading to 3-vinylindoles.<sup>14</sup>

We examined the possibility of preparing *N*-unsubstituted 3-pyrrolin-2-ones. We hypothesized that *tert*-butyl substrate **8f** would undergo the indolylation reaction in a similar fashion to the propyl substrate **8e**, and then subsequently, the *tert*-butyl group of the corresponding indole product **5f** could be removed under acidic conditions (e.g., treatment with TFA).

## Scheme 4. Possible Mechanism




In one of the early runs (Table 2, entry 1: PhCl, 100 °C, 0.5h), the indoloylation of **8f** gave a mixture of products that included deprotected product **5j** (31% yield) and deprotected tetramic acid **10** (40% yield). We were pleased to see that the *tert*-butyl group was indeed removable. Subjecting tetramic acid **10** to the PhCl/100 °C reaction conditions did not give product **5j** suggesting that *N*-substitution of the tetramic acid is required for the indoloylation to proceed. Under milder conditions (Table 2, entry 2: DCE, 65 °C, 12h), the protected product **5f** was obtained in just 17% yield.

To improve upon these results, we next assessed the inherent stability of the *tert*-butyl group of **8f** in the presence of BF<sub>3</sub>·Et<sub>2</sub>O in PhCl at a range of different temperatures (70 °C, 80 °C, 90 °C, 100 °C, 110 °C, 120 °C). We found that the *tert*-butyl group of **8f** was relatively stable at 70 and 80 °C (only traces of **10** detected after 1 h), whereas at higher temperatures, significant amounts of **10** could be detected after 1 h in the crude reaction mixtures. Using this information, we ran the indoloylation of **8f** at 80 °C followed by heating to 120 °C to remove the *tert*-butyl group of the presumed intermediate product **5f**. In addition, to help the indoloylation reaction compete with the deprotection, we used 5.0 equiv of **9a**. Under these conditions (Table 2, entry 3), we were able to obtain a 55% yield of **5j**. This result demonstrates that *N*-unprotected 3-pyrrolin-2-ones can be prepared from *tert*-butyl protected tetramic acid substrates.<sup>23</sup>


We next turned our attention to preparing fused carbazoles. We recently reported the use of Scholl-type oxidative cyclization reactions to transform 3,4-diaryl-3-pyrrolin-2-ones

into the corresponding dibenzo[*e,g*]isoindol-1-ones using the hypervalent iodine reagent, phenyliodine(III) bis(trifluoroacetate) (PIFA).<sup>11c,24</sup> Treatment of 4-indolylpyrrolones **5d**, **5h**, and **5j** with PIFA and BF<sub>3</sub>·Et<sub>2</sub>O gave the corresponding fused carbazoles **11d**, **11h**, and **11j** (Scheme 5).

Scheme 5. Synthesis of Benzo[*a*]carbazoles

To our knowledge, these benzo[*a*]carbazoles **11** represent the first reported examples of simple benzo[*a*]pyrrolo[3,4-*c*]carbazol-3-ones. As we observed earlier,<sup>11c</sup> 3,4-dimethoxyphenyl groups are superior to 4-methoxyphenyl groups in promoting the oxidative cyclization. Neither the 4-methoxyphenyl substrate **5c** nor the 4-fluorophenyl substrate **5b** yielded any of the corresponding benzo[*a*]carbazole products **11c** and **11b**.

Lastly, we applied our methodology to the preparation of the indolo[2,3-*a*]carbazole ring system (Scheme 6).<sup>25</sup> As men-

Scheme 6. Synthesis of Indolo[2,3-*a*]carbazole

tioned earlier, we had tried to prepare tetramic acid **8g** using the same chemistry depicted in Scheme 2 but this failed. We managed to successfully prepare **8g** using an alternate two-step strategy starting from *N*-methylindole-3-acetic acid (see

Table 2. *tert*-Butyl Substrate

entry	solvent	temp (°C)	time (h)	<b>5f</b> (%) <sup>a</sup>	<b>5j</b> (%) <sup>a</sup>	<b>10</b> (%) <sup>a</sup>
1	PhCl	100 °C	0.5	0	31	40
2	DCE	65 °C	12	17	0	<i>b</i>
3 <sup>c</sup>	PhCl	80 °C/120 °C <sup>d</sup>	3/1	<i>b</i>	55	<i>b</i>

<sup>a</sup>Isolated yield. <sup>b</sup>Not determined. <sup>c</sup>5.0 equiv of **9a** used. <sup>d</sup>After heating at 80 °C for 3h, reaction mixture was heated to 120 °C for 1 h.

Supporting Information). Treatment of **8g** with **9a** and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  in PhCl gave bisindole **5g** in 43% yield. Subsequent oxidative cyclization of **5g** mediated by PIFA and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  gave indolo[2,3-*a*]carbazole **11g** in 69% yield. Overall, this result represents a relatively short and potentially flexible strategy to indolocarbazoles.<sup>26</sup>

In conclusion, we have prepared indole-substituted 3-pyrrolin-2-ones using a direct arylation reaction between tetramic acids and simple indole substrates. The indole-substituted 3-pyrrolin-2-ones proved to be useful building blocks in the preparation of indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazoles and benzo[*a*]pyrrolo[3,4-*c*]carbazoles via Scholl-type oxidative cyclization reactions. The entire synthetic sequence involves only one chromatographic purification per final product and no precious metals or other costly reagents are required.

## EXPERIMENTAL SECTION

**General Methods.**<sup>11c</sup> *General Method A for the Preparation of Ethyl N-Alkylglycinates 6.* A modification of a literature procedure was followed.<sup>18b</sup> To a rt stirred solution of primary amine (400. mmol) in ether (200 mL) was added ethyl bromoacetate (5.5 mL, 50. mmol) dropwise via syringe. The reaction mixture was stirred at rt for 24–48 h (as noted) during which time a white precipitate forms. The reaction mixture was filtered to remove precipitate. The organic layer was washed with a saturated solution of sodium bicarbonate (100 mL) and brine (200 mL) and dried over sodium sulfate. Removal of the solvent in vacuo gave the ethyl *N*-alkylglycinates **6** as colorless oils, which were used directly without further purification.

*Ethyl N-Propylglycinate (6a).*<sup>18a</sup> Using general method A, propylamine (23.6 g, 32.9 mL, 400. mmol), and a reaction time of 24 h gave the title compound **6a** as a colorless oil (6.99 g, 48.2 mmol, 96% yield): IR (ATR, neat) 3332, 1736  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.19 (q,  $J = 7.2$  Hz, 2H), 3.40 (s, 2H), 2.57 (t,  $J = 7.2$  Hz, 2H), 1.73 (br s, 1H), 1.52 (sext,  $J = 7.2$  Hz, 2H), 1.28 (t,  $J = 7.2$  Hz, 3H), 0.93 (t,  $J = 7.6$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.9, 61.0, 51.8, 51.3, 23.5, 14.5, 12.0 ppm.

*Ethyl N-(tert-Butyl)glycinate (6b).*<sup>18b</sup> Using general method A, *tert*-butylamine (46.8 g, 67.3 mL, 640. mmol), and a reaction time of 48 h gave the title compound **6b** as a colorless oil (11.53 g, 72.41 mmol, 91% yield): IR (ATR, neat) 3330, 1737  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  4.19 (q,  $J = 7.2$  Hz, 2H), 3.39 (s, 2H), 1.59 (br s, 1H), 1.27 (t,  $J = 7.2$  Hz, 3H), 1.10 (s, 9H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  173.3, 61.1, 50.5, 45.2, 29.1, 14.5 ppm.

*General Method B for the Preparation of Methyl Arylacetates 7.* To a rt stirred solution of an arylacetic acid (100 mmol) in MeOH (200 mL) was added concentrated  $\text{H}_2\text{SO}_4$  (5.30 mL, 100 mmol) dropwise. The reaction mixture was heated to reflux for 1–24 h (as noted) and then cooled to 0 °C with the aid of an external ice bath. An aqueous solution of saturated  $\text{NaHCO}_3$  (100 mL) was added to the reaction mixture dropwise via an addition funnel. The bulk of the MeOH was then removed in vacuo and the residue was extracted with ether (2  $\times$  200 mL). The combined organics were dried over  $\text{Na}_2\text{SO}_4$ . Removal of the solvent in vacuo gave the methyl arylacetates **7**, which were used directly without further purification.

*Methyl 2-Phenylacetate (7a).*<sup>19c</sup> Using general method B, phenylacetic acid (10.00 g, 73.45 mmol), and a reaction time of 16 h gave the title compound **7a** as a colorless oil (10.40 g, 69.25 mmol, 94% yield):  $R_f = 0.80$  (1:2 EtOAc/petroleum ether); IR (ATR, neat) 1733  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.25–7.36 (m, 5H), 3.70 (s, 3H), 3.63 (s, 2H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.3, 134.2, 129.5, 128.9, 127.4, 52.4, 41.5 ppm.

*Methyl 2-(4'-Fluorophenyl)acetate (7b).*<sup>19e</sup> Using general method B, 2-(4'-fluorophenyl)acetic acid (10.0 g, 64.9 mmol), and a reaction time of 1.5 h gave the title compound **7b** as a colorless oil (8.77 g, 52.1 mmol, 80% yield):  $R_f = 0.84$  (1:1 EtOAc/petroleum ether); IR (ATR, neat) 1734  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.22–7.26 (m, 2H), 6.98–7.04 (m, 2H), 3.70 (s, 3H), 3.60 (s, 2H) ppm;  $^{13}\text{C}$  NMR (100

MHz,  $\text{CDCl}_3$ )  $\delta$  172.2 (d,  $J = 1.3$  Hz), 162.3 (d,  $J = 244$  Hz), 131.1 (d,  $J = 7.8$  Hz), 129.9 (d,  $J = 3.4$  Hz), 115.7 (d,  $J = 21$  Hz), 52.4, 40.6 ppm.

*Methyl 2-(3',4'-Dimethoxyphenyl)acetate (7d).*<sup>19</sup> Using general method B, 2-(3',4'-dimethoxyphenyl)acetic acid (5.00 g, 25.5 mmol), and a reaction time of 23 h gave the title compound **7d** as a light yellow oil (4.91 g, 23.4 mmol, 92% yield):  $R_f = 0.44$  (1:2 EtOAc/petroleum ether); IR (ATR, neat) 1732  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.82 (s, 3H), 3.88 (s, 3H), 3.87 (s, 3H), 3.70 (s, 3H), 3.57 (s, 2H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.6, 149.2, 148.4, 126.7, 121.7, 112.6, 111.5, 56.2, 56.1, 52.3, 41.0 ppm.

*Methyl 2-(2',3',4'-Trimethoxyphenyl)acetate (7e).*<sup>19a</sup> Using general method B, 2-(2',3',4'-dimethoxyphenyl)acetic acid (5.00 g, 22.1 mmol), and a reaction time of 23 h gave the title compound **7e** as a light yellow amorphous solid (4.362 g, 18.16 mmol, 82% yield): mp 35–38 °C (lit.<sup>19a</sup> mp 40.5–41.5 °C);  $R_f = 0.38$  (1:2 EtOAc/petroleum ether); IR (ATR, neat) 1734  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.50 (s, 2H), 3.86 (s, 6H), 3.83 (s, 3H), 3.71 (s, 3H), 3.56 (s, 2H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.3, 153.5, 137.3, 129.8, 106.5, 61.1, 56.4, 52.4, 41.7 ppm.

*Methyl 1-Methylindole-3-acetate (7g).*<sup>19b</sup> Using a modification of general method B (3 equiv of  $\text{H}_2\text{SO}_4$  and room temperature), 1-methylindole-3-acetic acid (3.00 g, 15.9 mmol), and a reaction time of 1 h gave the title compound **7g** as a reddish-brown oil (2.50 g, 12.3 mmol, 77% yield):  $R_f = 0.60$  (1:2 EtOAc/petroleum ether); IR (ATR, neat) 1731, 1616  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.59–7.61 (m, 1H), 7.29–7.32 (m, 1H), 7.22–7.26 (m, 1H), 7.11–7.15 (m, 1H), 7.05 (s, 1H), 3.78 (d,  $J = 0.8$  Hz, 2H), 3.77 (s, 3H), 3.70 (s, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.8, 137.1, 128.0, 127.9, 122.0, 119.4, 119.2, 109.5, 107.0, 52.2, 32.9, 31.3 ppm.

*General Method C for the Preparation of 3-Aryltetramic Acids 8.* A modification of a literature procedure by Le Gall and co-workers was followed.<sup>16</sup> To a rt stirred mixture of ethyl *N*-alkylglycinates **6** (30.0 mmol) and methyl arylacetates **7** (30.0 mmol) in THF (150 mL) was added solid *t*-BuOK (4.04 g, 36.0 mmol). The reaction mixture was heated to reflux for 2–24 h as noted. The reaction mixture was then cooled to 0 °C (with the aid of an external ice bath) and treated with an aqueous solution of  $\text{KHSO}_4$  (1.0 M, 120 mL) dropwise via addition funnel. After stirring the biphasic mixture for 15 min, the bulk of the THF was removed in vacuo. The resulting residue was extracted with EtOAc (4  $\times$  100 mL). The combined EtOAc layers were washed with brine (400 mL) and dried over sodium sulfate. The EtOAc layer was concentrated to approximately half the original volume and then placed in a refrigerator. The precipitate that formed was collected by filtration. The concentration/filtration sequence was repeated with the mother liquor 2–3 times and additional precipitate collected. The combined precipitated solids were dried in vacuo giving 3-aryltetramic acids as white (or close to white) powders, which were used without further purification. In some cases, treatment of the aqueous residue with EtOAc gave a precipitate which turned out to be the desired product; filtration before the drying step then gave an additional crop of product.

*4-Hydroxy-3-phenyl-1-propyl-1H-pyrrol-2(5H)-one (8a).* Using general method C, amine **6a** (4.36 g, 30.0 mmol), ester **7a** (4.51 g, 30.0 mmol), and a reaction time of 11 h gave the title compound **8a** as a white powder (5.18 g, 23.8 mmol, 79% yield): mp 217–222 °C;  $R_f = 0.38$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1661, 1584  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  11.61 (br s, 1H), 7.97 (dd,  $J = 1.0$ , 8.4 Hz, 2H), 7.27–7.32 (m, 2H), 7.12–7.16 (m, 1H), 3.93 (s, 2H), 3.28 (t,  $J = 7.2$  Hz, 2H), 1.51 (sext,  $J = 7.2$  Hz, 2H), 0.85 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  170.8, 166.6, 132.5, 127.7, 126.7, 125.4, 102.9, 48.9, 42.5, 21.3, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{13}\text{H}_{15}\text{NO}_2 \cdot \text{Na}$  240.0995, found 240.0996.

*3-(4'-Fluorophenyl)-4-hydroxy-1-propyl-1H-pyrrol-2(5H)-one (8b).* Using general method C, amine **6a** (2.90 g, 20.0 mmol), ester **7b** (3.36 g, 20.0 mmol), and a reaction time of 18 h gave the title compound **8b** as a white powder (2.95 g, 12.5 mmol, 65% yield): mp 220–225 °C;  $R_f = 0.31$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1663, 1581, 1560  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  11.71 (br s, 1H), 8.02–8.06 (m, 2H), 7.12–7.17 (m, 2H), 3.93 (s, 2H), 3.28 (t,  $J =$

7.2 Hz, 2H), 1.51 (sext,  $J = 7.2$  Hz, 2H), 0.84 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.7, 166.4 (d,  $J = 1.4$  Hz), 160.0 (d,  $J = 241$  Hz), 129.0 (d,  $J = 3.1$  Hz), 128.4 (d,  $J = 7.6$  Hz), 114.5 (d,  $J = 21.6$  Hz), 102.0, 48.9, 42.5, 21.2, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{13}\text{H}_{14}\text{FNO}_2\text{-Na}$  258.0901, found 258.0902.

**4-Hydroxy-3-(4'-methoxyphenyl)-1-propyl-1H-pyrrol-2(5H)-one (8c).** Using general method C, amine **6a** (2.18 g, 15.0 mmol), commercially available methyl 2-(4'-methoxyphenyl)acetate (**7c**) (2.70 g, 15.0 mmol), and a reaction time of 6 h gave the title compound **8c** as a white powder (1.97 g, 7.97 mmol, 53% yield): mp 212–220 °C;  $R_f = 0.35$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1663, 1582  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  11.40 (br s, 1H), 7.92 (d,  $J = 9.2$  Hz, 2H), 6.89 (d,  $J = 9.2$  Hz, 2H), 3.90 (s, 2H), 3.74 (s, 3H), 3.27 (t,  $J = 7.2$  Hz, 2H), 1.50 (sext,  $J = 7.2$  Hz, 2H), 0.84 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.1, 165.0, 157.0, 127.8, 125.0, 113.1, 102.7, 54.9, 48.9, 42.5, 21.3, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{14}\text{H}_{17}\text{NO}_3\text{-Na}$  270.1101, found 270.1102.

**4-Hydroxy-3-(3',4'-dimethoxyphenyl)-1-propyl-1H-pyrrol-2(5H)-one (8d).** Using general method C, amine **6a** (2.90 g, 20.0 mmol), ester **7d** (4.20 g, 20.0 mmol), and a reaction time of 18 h gave the title compound **8d** as a light yellow powder (3.00 g, 10.8 mmol, 54% yield): mp 204–210 °C;  $R_f = 0.18$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1660, 1582  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  11.42 (br s, 1H), 7.72 (d,  $J = 2.0$  Hz, 1H), 7.55 (dd,  $J = 2.0, 8.4$  Hz, 1H), 6.91 (d,  $J = 8.4$  Hz, 1H), 3.90 (s, 2H), 3.74 (s, 3H), 3.28 (t,  $J = 7.2$  Hz, 2H), 1.51 (sext,  $J = 7.2$  Hz, 2H), 0.85 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.0, 165.1, 147.9, 146.7, 125.4, 119.4, 111.4, 110.6, 102.7, 55.4, 55.3, 48.8, 42.5, 21.3, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{15}\text{H}_{19}\text{NO}_4\text{-Na}$  300.1206, found 300.1207.

**4-Hydroxy-3-(3',4',5'-trimethoxyphenyl)-1-propyl-1H-pyrrol-2(5H)-one (8e).** Using general method C, amine **6a** (2.91 g, 20.0 mmol), ester **7e** (4.81 g, 10.0 mmol), and a reaction time of 24 h gave the title compound **8e** as an off-white powder (2.58 g, 8.39 mmol, 42% yield): mp 190–196 °C;  $R_f = 0.15$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1662, 1590  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  11.67 (br s, 1H), 7.42 (s, 2H), 3.92 (s, 2H), 3.74 (s, 6H), 3.65 (s, 3H), 3.28 (t,  $J = 7.2$  Hz, 2H), 1.51 (sext,  $J = 7.2$  Hz, 2H), 0.84 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.9, 166.4, 152.2, 135.5, 128.2, 104.2, 102.5, 60.0, 55.6, 48.9, 42.5, 21.3, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{16}\text{H}_{21}\text{NO}_5\text{-Na}$  330.1312, found 330.1312.

**1-(tert-Butyl)-4-hydroxy-3-(3',4'-dimethoxyphenyl)-1H-pyrrol-2(5H)-one (8f).** Using general method C, amine **6b** (2.99 g, 18.8 mmol), ester **7d** (3.95 g, 18.8 mmol), and a reaction time of 22 h gave the title compound **8f** as a white fluffy powder (2.90 g, 9.95 mmol, 53% yield): mp 218–223 °C;  $R_f = 0.37$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1677, 1591  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  11.25 (br s, 1H), 7.68 (d,  $J = 2.0$  Hz, 1H), 7.50 (dd,  $J = 2.0, 8.8$  Hz, 1H), 6.89 (d,  $J = 8.8$  Hz, 1H), 3.95 (s, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 1.39 (s, 9H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.4, 164.5, 147.8, 146.7, 125.4, 119.6, 111.3, 110.7, 103.9, 55.4, 55.3, 52.7, 47.2, 27.7 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{16}\text{H}_{21}\text{NO}_4\text{-Na}$  314.1363, found 314.1364.

**General Method D for the Preparation of 3-Aryl-4-(indol-3'-yl)-3-pyrrolin-2-ones 5.** To a rt stirred mixture of tetramic acid **8** (2.00 mmol) and *N*-methylindole **9a** or indole **9b** (2.40 mmol) in PhCl (20 mL) was added 3 Å molecular sieves (1.0 g) followed by  $\text{BF}_3\text{-Et}_2\text{O}$  (0.43 g, 0.37 mL, 3.0 mmol). The reaction mixture was heated to 100 °C for 0.5 to 1.5 h (as noted) and then allowed to cool to rt and treated with MeOH (20 mL). The reaction mixture was decanted to remove the molecular sieves and the solvent was removed in vacuo. The residue was treated with  $\text{CH}_2\text{Cl}_2$  (20 mL) and silica gel (2.0 g) and the solvent was removed in vacuo (dry load). Purification by flash chromatography (EtOAc/petroleum ether gradient) gave the desired products as lightly colored amorphous solids.

**4-(1"-Methylindol-3"-yl)-3-phenyl-1-propyl-1H-pyrrol-2(5H)-one (5a).** Using general method D, tetramic acid **8a** (0.500 g, 2.30 mmol), *N*-methylindole (**9a**) (0.429 g, 3.27 mmol), and a reaction time of 1 h gave the title compound **5a** as a light yellow amorphous solid (0.640 g, 1.94 mmol, 84% yield): mp 43–47 °C;  $R_f = 0.44$  (1:1 EtOAc/

petroleum ether); IR (ATR, neat) 1660, 1597, 1571  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.49–7.52 (m, 2H), 7.29–7.36 (m, 4H), 7.16–7.24 (m, 2H), 7.09 (s, 1H), 7.00–7.04 (m, 1H), 4.46 (s, 2H), 3.73 (s, 3H), 3.57 (t,  $J = 7.2$  Hz, 2H), 1.74 (sext,  $J = 7.2$  Hz, 2H), 1.01 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.6, 143.2, 137.3, 133.9, 129.8, 129.6, 128.6, 128.5, 127.8, 125.7, 122.6, 121.3, 120.7, 110.0, 109.1, 53.4, 44.4, 33.4, 22.3, 11.8 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O-Na}$  353.1624, found 353.1624.

**3-(4'-Fluorophenyl)-4-(1"-methylindol-3"-yl)-1-propyl-1H-pyrrol-2(5H)-one (5b).** Using general method D, tetramic acid **8b** (0.500 g, 2.13 mmol), *N*-methylindole (**9a**) (0.335 g, 2.55 mmol), and a reaction time of 1 h gave the title compound **5b** as a light yellow amorphous solid (0.638 g, 1.83 mmol, 86% yield): mp 60–63 °C;  $R_f = 0.44$  (1:1 EtOAc/petroleum ether); IR (ATR, neat) 1735, 1661, 1599, 1571  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.47–7.52 (m, 2H), 7.31–7.33 (m, 1H), 7.21–7.25 (m, 1H), 7.11–7.13 (m, 1H), 7.10 (s, 1H), 6.98–7.04 (m, 3H), 4.43 (s, 2H), 3.76 (s, 3H), 3.56 (t,  $J = 7.2$  Hz, 2H), 1.73 (sext,  $J = 7.2$  Hz, 2H), 1.0 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.5, 162.5 (d,  $J = 24.6$  Hz), 143.2, 137.4, 131.6 (d,  $J = 7.9$  Hz), 129.8 (d,  $J = 3.4$  Hz), 129.4, 126.4, 125.5, 122.7, 121.3, 120.8, 115.6 (d,  $J = 21.3$  Hz), 110.0, 109.0, 53.4, 44.4, 33.5, 22.3, 11.7 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{22}\text{H}_{21}\text{FN}_2\text{O-Na}$  371.1530, found 371.1530.

**3-(4'-Methoxyphenyl)-4-(1"-Methylindol-3"-yl)-1-propyl-1H-pyrrol-2(5H)-one (5c).** Using general method D, tetramic acid **8c** (1.00 g, 4.04 mmol), *N*-methylindole (**9a**) (0.636 g, 4.85 mmol), and a reaction time of 1 h gave the title compound **5c** as a yellow powder (1.11 g, 3.08 mmol, 76% yield): mp 132–133 °C;  $R_f = 0.36$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1663, 1605  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.46 (d,  $J = 8.8$  Hz, 2H), 7.30–7.33 (m, 1H), 7.20–7.24 (m, 2H), 7.12 (s, 1H), 7.01–7.05 (m, 1H), 6.87 (d,  $J = 8.8$  Hz, 2H), 4.43 (s, 2H), 3.82 (s, 3H), 3.74 (s, 3H), 3.56 (t,  $J = 7.2$  Hz, 2H), 1.72 (sext,  $J = 7.2$  Hz, 2H), 1.00 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.8, 159.3, 142.1, 137.3, 131.0, 129.4, 128.1, 126.3, 125.8, 122.5, 121.4, 120.7, 114.1, 110.0, 109.3, 55.5, 53.4, 44.4, 33.4, 22.3, 11.8 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}_2\text{-Na}$  383.1730, found 383.1728.

**3-(3',4'-Dimethoxyphenyl)-4-(1"-methylindol-3"-yl)-1-propyl-1H-pyrrol-2(5H)-one (5d).** Using general method D, tetramic acid **8d** (0.150 g, 0.541 mmol), *N*-methylindole (**9a**) (0.085 g, 0.65 mmol), and a reaction time of 1 h gave the title compound **5d** as a yellow amorphous solid (0.172 g, 0.440 mmol, 81% yield): mp 66–69 °C;  $R_f = 0.35$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1654, 1604  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.30–7.33 (m, 1H), 7.18–7.25 (m, 2H), 7.08–7.14 (m, 3H), 7.02–7.06 (m, 1H), 6.83 (d,  $J = 9.2$  Hz, 1H), 4.43 (s, 2H), 3.88 (s, 3H), 3.75 (s, 3H), 3.70 (s, 3H), 3.56 (t,  $J = 7.2$  Hz, 2H), 1.73 (sext,  $J = 7.2$  Hz, 2H), 1.00 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.7, 148.9, 148.8, 143.0, 137.3, 129.5, 128.0, 126.5, 125.7, 122.6, 122.5, 121.5, 120.8, 112.9, 111.4, 110.0, 109.3, 56.1, 56.0, 55.4, 44.4, 33.4, 22.3, 11.8 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_3\text{-Na}$  413.1836, found 413.1834.

**3-(3',4',5'-Trimethoxyphenyl)-4-(1"-methylindol-3"-yl)-1-propyl-1H-pyrrol-2(5H)-one (5e).** Using general method D, tetramic acid **8e** (0.250 g, 0.813 mmol), *N*-methylindole (**9a**) (0.128 g, 0.976 mmol), and a reaction time of 1 h gave the title compound **5e** as a white film (0.224 g, 0.533 mmol, 66% yield): mp 45–50 °C;  $R_f = 0.26$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1660, 1620, 1578  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.30–7.33 (m, 1H), 7.17–7.25 (m, 2H), 7.15 (s, 1H), 7.03–7.07 (m, 1H), 6.78 (s, 2H), 4.46 (s, 2H), 3.85 (s, 3H), 3.76 (s, 3H), 3.66 (s, 6H), 3.57 (t,  $J = 7.2$  Hz, 2H), 1.73 (sext,  $J = 7.2$  Hz, 2H), 1.01 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.5, 153.4, 143.0, 137.8, 137.3, 129.7, 129.2, 127.8, 125.5, 122.7, 121.5, 120.9, 110.0, 109.0, 107.0, 61.1, 56.2, 53.3, 44.4, 33.5, 22.3, 11.7 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{25}\text{H}_{28}\text{N}_2\text{O}_4\text{-Na}$  443.1941, found 443.1938.

**3-(3',4'-Dimethoxyphenyl)-4-(indol-3"-yl)-1-propyl-1H-pyrrol-2(5H)-one (5h).** Using general method D, tetramic acid **8d** (0.500 g, 1.80 mmol), indole (**9b**) (0.634 g, 5.41 mmol), and a reaction time of 1.5 h gave the title compound **5h** as a light yellow amorphous solid (0.195 g, 0.518 mmol, 29% yield): mp 184–187 °C;  $R_f = 0.27$  (2:1

EtOAc/petroleum ether); IR (ATR, neat) 3351, 3230, 1731, 1647, 1603  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  11.54 (br s, 1H), 7.59 (d,  $J = 2.8$  Hz, 1H), 7.39 (d,  $J = 8.4$  Hz, 1H), 7.04–7.09 (m, 1H), 7.01 (dd,  $J = 2.0, 8.4$  Hz, 1H), 6.81–6.93 (m, 4H), 4.49 (s, 2H), 3.74 (s, 3H), 3.43 (m, 2H), 3.33 (s, 3H), 1.64 (sext,  $J = 7.2$  Hz, 2H), 0.91 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  170.4, 148.02, 148.01, 143.2, 136.4, 126.4, 126.2, 126.0, 124.1, 121.8, 121.7, 120.8, 119.6, 113.0, 111.9, 111.4, 109.0, 55.4, 55.0, 52.5, 43.4, 21.4, 11.4 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}_3\cdot\text{Na}$  399.1679, found 399.1677.

**1-(tert-Butyl)-3-(3',4'-dimethoxyphenyl)-4-(1"-methylindol-3"-yl)-1H-pyrrol-2(5H)-one (5f).** Using a modification of general method D (solvent = DCE; reaction temperature = 65 °C), tetramic acid **8f** (0.200 g, 0.686 mmol), *N*-methylindole (**9a**) (0.108 g, 0.824 mmol), and a reaction time of 12 h gave the title compound as an off-white amorphous solid (46 mg, 0.11 mmol, 17% yield): mp 141–145 °C;  $R_f = 0.50$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1654, 1602  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.28–7.32 (m, 1H), 7.19–7.24 (m, 1H), 7.15–7.17 (m, 1H), 7.13 (s, 1H), 7.06–7.11 (m, 2H), 7.00–7.04 (m, 1H), 6.82 (d,  $J = 8.4$  Hz, 1H), 4.47 (s, 2H), 3.87 (s, 3H), 3.75 (s, 3H), 3.68 (s, 3H), 1.58 (s, 9H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  171.9, 148.9, 148.7, 141.6, 137.3, 129.35, 129.30, 126.4, 125.6, 122.7, 122.5, 121.6, 120.7, 113.0, 111.4, 109.9, 109.3, 56.14, 56.08, 54.3, 51.7, 33.4, 28.4 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{25}\text{H}_{28}\text{N}_2\text{O}_3\cdot\text{Na}$  427.1992, found 427.1989.

**3-(3',4'-Dimethoxyphenyl)-4-(1"-methylindol-3"-yl)-1H-pyrrol-2(5H)-one (5j).** Using general method D, tetramic acid **8f** (0.500 g, 1.72 mmol), *N*-methylindole (**9a**) (0.270 g, 2.06 mmol), and a reaction time of 0.5 h gave the title compound **5j** as a light yellow amorphous solid (0.814 g, 0.528 mmol, 31% yield). Trituration ( $\text{CH}_2\text{Cl}_2$ /pentane) gave an analytical sample of **5j** as an off-white powder: mp 83–86 °C;  $R_f = 0.30$  (1:9 MeOH/EtOAc); IR (ATR, neat) 3214, 1731, 1660, 1600  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  8.23 (br s, 1H), 7.65 (s, 1H), 7.45 (d,  $J = 8.4$  Hz, 1H), 7.10–7.14 (m, 1H), 6.99 (dd,  $J = 2.0, 8.4$  Hz, 1H), 6.93 (d,  $J = 2.0$  Hz, 1H), 6.88 (d,  $J = 8.4$  Hz, 1H), 6.82–6.86 (m, 1H), 6.77 (d,  $J = 8.0$  Hz, 1H), 4.35 (d,  $J = 1.2$  Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.42 (s, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  173.3, 148.01, 147.95, 144.8, 137.0, 130.3, 126.3, 126.0, 124.4, 121.9, 121.7, 121.0, 119.7, 113.1, 111.4, 110.1, 108.5, 55.4, 55.1, 47.9, 32.8 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_3\cdot\text{Na}$  371.1366, found 371.1366. In a subsequent experiment using general method D, tetramic acid **8f** (57 mg, 0.20 mmol), *N*-methylindole (**9a**) (131 mg, 1.00 mmol), in PhCl (5 mL) with heating at 80 °C for 3h followed by heating at 120 °C for 1h, the title compound **5j** (39 mg, 0.11 mmol) was obtained in 55% yield.

**3-(3,4-Dimethoxyphenyl)-4-hydroxy-1H-pyrrol-2(5H)-one (10).** Using general method D, tetramic acid **8f** (0.500 g, 1.72 mmol), *N*-methylindole (**9a**) (0.270 g, 2.06 mmol), and a reaction time of 0.5 h gave the title compound **10** (after elution of **5j**) as a white amorphous solid (0.164 g, 0.697 mmol, 40% yield): mp 234–237 (dec) °C;  $R_f = 0.25$  (1:9 MeOH/EtOAc); IR (ATR, neat) 3349, 1666, 1613, 1602, 1582  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  11.38 (br s, 1H), 7.70 (d,  $J = 2.0$  Hz, 1H), 7.55 (dd,  $J = 2.0, 8.6$  Hz, 1H), 7.41 (br s, 1H), 6.90 (d,  $J = 8.6$  Hz, 1H), 3.83 (d,  $J = 0.8$  Hz, 2H), 3.73 (s, 3H), 3.72 (s, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  174.0, 167.4, 147.9, 146.7, 125.4, 119.5, 111.3, 110.7, 102.9, 55.4, 55.3, 44.7 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{12}\text{H}_{13}\text{NO}_4\cdot\text{Na}$  258.0737, found 258.0739.

**General Method E for the Oxidative Cyclization to Fused Carbazoles 11.** A modification of a literature procedure was followed.<sup>11c</sup> A mixture of 3-pyrrolin-2-one **5** (0.20 mmol) and phenyliodine(III) bis(trifluoroacetate) (PIFA) (95 mg, 0.22 mmol) in  $\text{CH}_2\text{Cl}_2$  (10 mL) in 20 mL vial with a septum-style cap was cooled to –40 °C using an external cooling bath (acetonitrile/dry ice). To the cooled reaction mixture was added  $\text{BF}_3\cdot\text{Et}_2\text{O}$  dropwise via syringe. The reaction mixture was stirred at –40 °C for 3.5–4 h (as noted). The bulk of the solvent was then removed and the crude residue was treated with EtOH (10 mL) and the solution was transferred to a centrifuge tube and placed in a freezer (–20 °C) until a product precipitated. Centrifugation, decantation of the solvent, and drying in vacuo gave the desired products as colored powders.

**1,2-Dihydro-5,6-dimethoxy-8-methyl-2-propylbenzo[a]pyrrolo[3,4-c]carbazol-3(8H)-one (11d).** Using general method E, 3-pyrrolin-2-one **5d** (0.100 g, 0.256 mmol), and a reaction time of 3.5 h gave title compound **11d** as a pink powder (54.6 mg, 0.141 mmol, 55% yield): mp 205–210 °C;  $R_f = 0.63$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1661, 1629, 1578  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.88 (s, 1H), 8.15 (s, 1H), 8.00 (d,  $J = 7.6$  Hz, 1H), 7.83 (d,  $J = 8.4$  Hz, 1H), 7.51–7.55 (m, 1H), 7.32–7.36 (m, 1H), 4.87 (s, 2H), 4.43 (s, 3H), 4.04 (s, 3H), 3.95 (s, 3H), 3.59 (t,  $J = 7.2$  Hz, 2H), 1.75 (sext,  $J = 7.2$  Hz, 2H), 0.94 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  169.3, 148.9, 147.9, 140.6, 136.7, 136.2, 124.7, 124.4, 121.1, 120.7, 120.1, 116.7, 116.3, 111.7, 110.0, 103.5, 103.4, 55.3, 55.2, 48.5, 43.3, 33.6, 21.4, 11.4 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{24}\text{H}_{24}\text{N}_2\text{O}_3\cdot\text{Na}$  411.1679, found 411.1679.

**1,2-Dihydro-5,6-dimethoxy-2-propylbenzo[a]pyrrolo[3,4-c]carbazol-3(8H)-one (11h).** Using general method E, 3-pyrrolin-2-one **5h** (0.116 g, 0.310 mmol), and a reaction time of 4 h gave title compound **11h** as a light brown powder (49.9 mg, 0.133 mmol, 43% yield): mp 179–184 °C;  $R_f = 0.52$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 3302, 1630, 1584  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  12.36 (br s, 1H), 8.74 (s, 1H), 8.07 (s, 1H), 8.03 (d,  $J = 7.6$  Hz, 1H), 7.69 (d,  $J = 8.0$  Hz, 1H), 7.43–7.48 (m, 1H), 7.27–7.32 (m, 1H), 4.96 (s, 2H), 4.01 (s, 3H), 3.94 (s, 3H), 3.61 (t,  $J = 7.2$  Hz, 2H), 1.75 (sext,  $J = 7.2$  Hz, 2H), 0.94 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  169.5, 149.5, 148.6, 138.9, 137.4, 136.5, 124.7, 123.2, 122.3, 120.9, 119.9, 116.5, 115.5, 111.4, 111.0, 103.5, 102.6, 55.6, 55.3, 48.6, 43.3, 21.4, 11.4 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_3\cdot\text{Na}$  397.1523, found 397.1523.

**1,2-Dihydro-5,6-dimethoxy-8-methylbenzo[a]pyrrolo[3,4-c]carbazol-3(8H)-one (11j).** Using general method E, 3-pyrrolin-2-one **5j** (59 mg, 0.17 mmol), and a reaction time of 3.5 h gave title compound **11j** as a brown powder (49 mg, 0.14 mmol, 83% yield): mp >300 °C;  $R_f = 0.35$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 3382, 1663, 1630, 1579  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.88 (s, 1H), 8.53 (br s, 1H), 8.20 (s, 1H), 7.99 (d,  $J = 7.6$  Hz, 1H), 7.85 (d,  $J = 8.4$  Hz, 1H), 7.50–7.55 (m, 1H), 7.31–7.35 (m, 1H), 4.83 (s, 2H), 4.47 (s, 3H), 4.05 (s, 3H), 3.94 (s, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  172.3, 148.8, 147.8, 140.5, 138.6, 136.8, 124.6, 121.2, 120.6, 120.0, 116.6, 116.2, 111.8, 109.9, 103.5, 103.2, 55.24, 55.21, 43.9, 33.5 (missing one peak) ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_3\cdot\text{Na}$  369.1210, found 369.1210.

**Ethyl 2-(2-(1-Methyl-1H-indol-3-yl)-*N*-propylacetamido)acetate (i).** To a rt stirred mixture of commercially available *N*-methylindole-3-acetic acid (3.00 g, 15.9 mmol) and DCC (3.94 g, 19.1 mmol) in  $\text{CH}_2\text{Cl}_2$  was added amine **6a** (2.53 g, 17.4 mmol) and DMAP (0.194 g, 1.59 mmol). The reaction mixture was stirred at rt for 2.5 h and then the precipitate which formed was removed by filtration (twice). The solution was treated with an aqueous solution of  $\text{KHSO}_4$  (1.0 M, 100 mL) and the organic layer was separated. The aqueous layer was re-extracted with  $\text{CH}_2\text{Cl}_2$  (100 mL). The combined organic layers were washed with brine (200 mL) and dried over  $\text{Na}_2\text{SO}_4$ . Removal of the solvent in vacuo gave a crude brown oil (5.4 g) which was purified by flash chromatography (EtOAc/petroleum ether gradient). Fractions containing product were filtered (traces of DCU) and the solvent was removed in vacuo to give the title compound **i** as a pink oil (2.99 g, 9.45 mmol, 60% yield). Upon standing at rt for a week, the oil solidified into a light pink powder: mp 47–49 °C;  $R_f = 0.47$  (1:1 EtOAc/petroleum ether); IR (ATR, neat) 1745, 1636  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  (mixture of rotamers) 7.55–7.58 (m, 1H), 7.27–7.31 (m, 1H), 7.21–7.25 (m, 1H), 7.09–7.14 (m, 1H), 6.97 and 7.14 (s, 1H), 4.10–4.26 (m, 2H), 4.03 and 4.09 (s, 2H), 3.86 (d,  $J = 0.8$  Hz, 2H), 3.75 and 3.77 (s, 3H), 3.31–3.35 (m, 2H), 1.51–1.56 (m, 2H), 1.20–1.30 (m, 3H), 0.84–0.89 (m, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  (major rotamer) 172.3, 169.80, 137.1, 127.9, 127.7, 121.9, 119.2, 118.8, 109.5, 107.7, 61.3, 51.5, 47.9, 33.00, 30.8, 22.3, 14.4, 11.4 ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  (minor rotamer) 172.0, 169.83, 127.8, 127.6, 122.0, 119.4, 119.0, 110.3, 109.4, 107.4, 61.7, 50.4, 49.5, 32.97, 31.7, 20.9, 14.3, 11.6 ppm of HRMS (ESI-FTICR) calcd for  $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_3\cdot\text{Na}$  339.1679, found 339.1678.

1-(tert-Butyl)-4-hydroxy-3-(1'-methylindol-3'-yl)-1H-pyrrol-2(5H)-one (**8g**). Using general method C, amide **i** (3.46 g, 10.9 mmol), and a reaction time of 2 h gave the title compound **8g** as a white powder (2.445 g, 9.045 mmol, 83% yield): mp 220–228 °C;  $R_f = 0.31$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1682, 1595  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  10.94 (br s, 1H), 7.95–7.98 (m, 1H), 7.62 (s, 1H), 7.36–7.39 (m, 1H), 7.10–7.14 (m, 1H), 6.97–7.01 (m, 1H), 3.95 (s, 2H), 3.78 (s, 3H), 3.31 (t,  $J = 7.2$  Hz, 2H), 1.53 (sext,  $J = 7.2$  Hz, 2H), 0.87 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  171.5, 162.1, 136.1, 128.0, 126.4, 122.3, 120.9, 118.2, 109.2, 105.5, 100.7, 49.2, 42.8, 32.4, 21.4, 11.3 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_2\text{-Na}$  293.1266, found 293.1261.

3,4-Bis(1'-methylindol-3'-yl)-1-propyl-1H-pyrrol-2(5H)-one (**5g**). Using general method D, tetramic acid **8g** (0.500 g, 1.85 mmol), N-methylindole (**9a**) (0.291 g, 2.22 mmol), and a reaction time of 0.5 h gave the title compound **5g** as an off-white film (0.307 g, 0.801 mmol, 43% yield). Trituration ( $\text{CH}_2\text{Cl}_2/\text{pentane}$ ) gave an analytical sample of **5g** as an off-white powder: mp 195–199 °C;  $R_f = 0.44$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1670, 1630, 1608  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.62–7.64 (m, 1H), 7.62 (s, 1H), 7.31–7.34 (m, 2H), 7.23–7.28 (m, 1H), 7.12–7.17 (m, 2H), 7.00 (s, 1H), 6.96–6.98 (m, 1H), 6.82–6.86 (m, 1H), 4.63 (s, 2H), 3.87 (s, 3H), 3.61 (t,  $J = 7.2$  Hz, 2H), 3.57 (s, 3H), 1.76 (sext,  $J = 7.2$  Hz, 2H), 1.01 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.4, 140.2, 137.3, 137.0, 131.2, 130.9, 126.5, 125.4, 122.4, 122.3, 121.5, 120.9, 120.7, 119.1, 110.1, 109.53, 109.50, 107.4, 53.5, 44.6, 33.3, 33.2, 22.3, 11.8 (missing one peak) ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{25}\text{H}_{25}\text{N}_3\text{O}$ -Na 406.1890, found 406.1889.

12,13-Dimethyl-6,7,12,13-tetrahydro-6-propyl-5H-indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazol-5-one (**11g**). Using general method E, 3-pyrrolin-2-one **5g** (50 mg, 0.13 mmol), and a reaction time of 4 h gave title compound **11g** as a light brown powder (34 mg, 0.89 mmol, 69% yield): mp 258–260 °C;  $R_f = 0.73$  (2:1 EtOAc/petroleum ether); IR (ATR, neat) 1661, 1618, 1589  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{D}_6\text{-DMSO}$ )  $\delta$  9.43 (d,  $J = 7.6$  Hz, 1H), 8.10 (d,  $J = 7.6$  Hz, 1H), 7.79 (d,  $J = 8.4$  Hz, 1H), 7.71 (d,  $J = 8.4$  Hz, 1H), 7.57–7.61 (m, 1H), 7.52–7.56 (m, 1H), 7.37–7.41 (m, 1H), 7.27–7.31 (m, 1H), 5.06 (s, 2H), 4.29 (s, 3H), 4.25 (s, 3H), 3.65 (t,  $J = 7.2$  Hz, 2H), 1.79 (sext,  $J = 7.2$  Hz, 2H), 0.96 (t,  $J = 7.2$  Hz, 3H) ppm;  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.3, 144.3, 144.0, 131.7, 130.6, 129.8, 126.7, 126.3, 125.9, 124.2, 123.8, 121.1, 121.0, 120.8, 120.4, 119.9, 116.9, 110.7, 109.9, 50.3, 44.7, 37.1, 36.9, 22.4, 11.8 ppm; HRMS (ESI-FTICR) calcd for  $\text{C}_{25}\text{H}_{23}\text{N}_3\text{O}$ -Na 404.1733, found 404.1733.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b01072.

$^1\text{H}$  NMR spectra and  $^{13}\text{C}$  NMR spectra for all synthesized compounds (PDF)

## AUTHOR INFORMATION

### Corresponding Author

\*E-mail: pelkey@hws.edu

### Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

Financial support of this research from the NSF (RUI: 1362813), Hobart and William Smith Colleges, Drs. Carey and Cohen (M.H.K.), Dr. Edward Franks, and the Patchett Family is gratefully acknowledged.

## REFERENCES

(1) Indolo[2,3-*a*]carbazole reviews: (a) Gribble, G. W.; Berthel, S. J. *Stud. Nat. Prod. Chem.* **1993**, *12*, 365–409. (b) Sanchez, C.; Mendez,

C.; Salas, J. A. *Nat. Prod. Rep.* **2006**, *23*, 1007–1045. (c) Janosik, T.; Wahlström, N.; Bergman, J. *Tetrahedron* **2008**, *64*, 9159–9180.

(2) Recent selected syntheses of indolo[2,3-*a*]carbazoles: (a) Viji, M.; Ghosh, S. K.; Nagarajan, R. *Synthesis* **2014**, *46*, 955–961. (b) Borrero, N. V.; DeRatt, L. G.; Barbosa, L. F.; Abboud, K. A.; Aponick, A. *Org. Lett.* **2015**, *17*, 1754–1757. (c) Fox, J. C.; Gilligan, R. E.; Pitts, A. K.; Bennett, H. R.; Gaunt, M. J. *Chem. Sci.* **2016**, *7*, 2706–2710.

(3) Nakano, H.; Omura, S. *J. Antibiot.* **2009**, *62*, 17–26.

(4) Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. *Biochem. Biophys. Res. Commun.* **1986**, *135*, 397–402.

(5) (a) Hudkins, R. L.; Park, C. H. *J. Heterocycl. Chem.* **2003**, *40*, 135–142. (b) Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. *J. Med. Chem.* **2003**, *46*, 5375–5388. (c) Tao, M.; Park, C. H.; Josef, K.; Hudkins, R. L. *J. Heterocycl. Chem.* **2009**, *46*, 1185–1189.

(6) (a) Hudkins, R. L.; Johnson, N. W. *J. Heterocycl. Chem.* **2001**, *38*, 591–595. (b) Hudkins, R. L.; Johnson, N. W.; Angeles, T. S.; Gessner, G. W.; Mallamo, J. P. *J. Med. Chem.* **2007**, *50*, 433–441.

(7) Hudkins, R. L.; Becknell, N. C.; Zulli, A. L.; Underiner, T. L.; Angeles, T. S.; Aimone, L. D.; Albom, M. S.; Chang, H.; Miknyoczki, S. J.; Hunter, K.; Jones-Bolin, S.; Zhao, H.; Bacon, E. R.; Mallamo, J. P.; Ator, M. A.; Ruggeri, B. A. *J. Med. Chem.* **2012**, *55*, 903–913.

(8) Pili, R.; Carducci, M.; Brown, P.; Hurwitz, H. *Invest. New Drugs* **2014**, *32*, 1258–1268.

(9) Preparation of a benzo[*a*]pyrrolo[3,4-*c*]carbazol-1-one, a regioisomer of **3**, has been reported: Conchon, E.; Anizon, F.; Aboab, B.; Prudhomme, M. *Synthesis* **2008**, *2008*, 2569–2574.

(10) Preparation of benzo[*a*]pyrrolo[3,4-*c*]carbazol-1,3-diones, malimide derivatives of **3**, have been reported: (a) Harris, W.; Hill, C. H.; Keech, E.; Malsher, P. *Tetrahedron Lett.* **1993**, *34*, 8361–8364. (b) Sanchez-Martinez, C.; Faul, M. M.; Shih, C.; Sullivan, K. A.; Grutsch, J. L.; Cooper, J. T.; Kolis, S. P. *J. Org. Chem.* **2003**, *68*, 8008–8014. (c) Routier, S.; Mérour, J.-Y.; Dias, N.; Lansiaux, A.; Bailly, C.; Lozach, O.; Meijer, L. *J. Med. Chem.* **2006**, *49*, 789–799. (d) Tao, M.; Park, C. H.; Bihovsky, R.; Wells, G. J.; Husten, J.; Ator, M. A.; Hudkins, R. L. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 938–942. (e) Peifer, C.; Stoiber, T.; Unger, E.; Totzke, F.; Schächtele, C.; Marmé, D.; Brenk, R.; Klebe, G.; Schollmeyer, D.; Dannhardt, G. *J. Med. Chem.* **2006**, *49*, 1271–1281. (f) Conchon, E.; Anizon, F.; Aboab, B.; Prudhomme, M. *J. Med. Chem.* **2007**, *50*, 4669–4680. (g) Li, L.; Shao, X.; Cole, E. L.; Ohnmacht, S. A.; Ferrari, V.; Hong, Y. T.; Williamson, D. J.; Fryer, T. D.; Quesada, C. A.; Sherman, P.; Riss, P. J.; Scott, P. J. H.; Aigbirio, F. I. *ACS Med. Chem. Lett.* **2015**, *6*, 548–552.

(11) (a) Dorward, K. M.; Guthrie, N. J.; Pelkey, E. T. *Synthesis* **2007**, *2007*, 2317–2322. (b) Yoon-Miller, S. J. P.; Dorward, K. M.; White, K. P.; Pelkey, E. T. *J. Heterocycl. Chem.* **2009**, *46*, 447–454. (c) van Loon, A. A.; Holton, M. K.; Downey, C. R.; White, T. M.; Rolph, C. E.; Bruening, S. R.; Li, G.; Delaney, K. M.; Pelkey, S. J.; Pelkey, E. T. *J. Org. Chem.* **2014**, *79*, 8049–8058.

(12) For our alternate strategy to 3,4-diaryl-3-pyrrolin-2-ones **4** via pyrrole Weinreb amides: (a) Coffin, A. R.; Roussel, M. A.; Tserlin, E.; Pelkey, E. T. *J. Org. Chem.* **2006**, *71*, 6678–6681. (b) Greger, J. G.; Yoon-Miller, S. J. P.; Bechtold, N. R.; Flewelling, S. A.; MacDonald, J. P.; Downey, C. R.; Cohen, E. A.; Pelkey, E. T. *J. Org. Chem.* **2011**, *76*, 8203–8214.

(13) 3-Pyrrolin-2-one review: Pelkey, E. T.; Pelkey, S. J.; Greger, J. G. *Adv. Heterocycl. Chem.* **2015**, *115*, 151–285.

(14) For direct indole substitution reactions involving ketone electrophiles: (a) Freter, K. *J. Org. Chem.* **1975**, *40*, 2525–2529. (b) Arcadi, A.; Alfonsi, M.; Bianchi, G.; D'Annibale, G.; Marinelli, F. *Adv. Synth. Catal.* **2006**, *348*, 331–338. (c) Yadav, J. S.; Reddy, B. V. S.; Praneeth, K. *Tetrahedron Lett.* **2008**, *49*, 199–202. (d) Santra, S.; Majee, A.; Hajra, A. *Tetrahedron Lett.* **2011**, *52*, 3825–3827. (e) Singh, N.; Singh, K. N. *Synlett* **2012**, *23*, 2116–2121.

(15) Gaudencio, S. P.; Santos, M. M. M.; Lobo, A. M.; Prabhakar, S. *Tetrahedron Lett.* **2003**, *44*, 2577–2578.

(16) Mallinger, A.; Nadal, B.; Chopin, N.; Le Gall, T. *Eur. J. Org. Chem.* **2010**, *2010*, 1142–1148.

(17) Alternate syntheses of 3-aryltetramic acids: (a) King, J. A.; McMillan, F. H. *J. Am. Chem. Soc.* **1950**, *72*, 1236–1240. (b) Andrews, M. D.; Brewster, A. G.; Chuhan, J.; Ibbett, A. J.; Moloney, M. G.; Prout, K.; Watkin, D. *Synthesis* **1997**, *1997*, 305–308. (c) Anwar, M.; Moloney, M. G. *Tetrahedron Lett.* **2007**, *48*, 7259–7262. (d) Miyazaki, H.; Ogiku, T.; Sai, H.; Moritani, Y.; Ohtani, A.; Ohmizu, H. *Chem. Pharm. Bull.* **2009**, *57*, 979–985. (e) Storgaard, M.; Dörwald, F. Z.; Peschke, D.; Tanner, J. *J. Org. Chem.* **2009**, *74*, 5032–5040. (f) García-Aranda, M. I.; García-López, M. T.; de Vega, M. J. P.; González-Muñiz, R. *Tetrahedron Lett.* **2014**, *55*, 2142–2145.

(18) (a) Kier, L. B.; Dhawan, D. *J. Pharm. Sci.* **1962**, *51*, 1058–1061. (b) Pospíšil, J.; Potáček, M. *Tetrahedron* **2007**, *63*, 337–346.

(19) (a) Sober, D. J.; Chang, J.; Fowble, J. W.; Mukhopadhyay, A.; Feller, D. R.; Miller, D. D.; Fairchild, E. H. *J. Med. Chem.* **1981**, *24*, 970–974. (b) Karp, G. M. *J. Org. Chem.* **1995**, *60*, 5814–5819. (c) Roy, S.; Roy, S.; Gribble, G. W. *Org. Lett.* **2006**, *8*, 4975–4977. (d) Harker, W. R. R.; Carswell, E. L.; Carbery, D. R. *Org. Lett.* **2010**, *12*, 3712–3715. (e) Molander, G. A.; Traister, K. M.; Barcellos, T. *J. Org. Chem.* **2013**, *78*, 4123–4131.

(20) (a) López-Valdez, G.; Olguín-Urbe, S.; Millan-Ortiz, A.; Gamez-Montaña, R.; Miranda, L. D. *Tetrahedron* **2011**, *67*, 2693–2701. (b) Olimpieri, F.; Bellucci, M. C.; Marcelli, T.; Volonterio, A. *Org. Biomol. Chem.* **2012**, *10*, 9538–9555. (c) Sakthivel, K.; Srinivasan, K. *Eur. J. Org. Chem.* **2013**, *2013*, 3386–3396. (d) Evans, V.; Mahon, M. F.; Webster, R. L. *Tetrahedron* **2014**, *70*, 7593–7597.

(21) In one control experiment, we combined equimolar amounts of **5c** and **8c** and  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  in PhCl at 100 °C and found that the product **8c** degraded faster than the starting material **5c**.

(22) Illi, V. O. *Synthesis* **1979**, *1979*, 136.

(23) We briefly explored the use of a 3,4-dimethoxybenzyl as a protecting group using a substrate available to us from a previous study (reference **11a**, compound **4a**), and we obtained intractable mixtures that did not appear to contain product by analysis of  $^1\text{H}$  NMR.

(24) For leading references for the Scholl-type oxidative cyclization: (a) Kovacic, P.; Jones, M. B. *Chem. Rev.* **1987**, *87*, 357–359. (b) King, B. T.; Kroulik, J.; Robertson, C. R.; Rempala, P.; Hilton, C. L.; Korinek, J. D.; Gortari, L. M. *J. Org. Chem.* **2007**, *72*, 2279–2288. (c) Zhai, L.; Shukla, R.; Wadumethrige, S. H.; Rathore, R. *J. Org. Chem.* **2010**, *75*, 4748–4760. (d) Grzybowski, M.; Skonieczny, K.; Butenschön, H.; Gryko, D. T. *Angew. Chem., Int. Ed.* **2013**, *52*, 9900–9930.

(25) For PIFA-mediated oxidative cyclizations to indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazoles: Faul, M. M.; Sullivan, K. A. *Tetrahedron Lett.* **2001**, *42*, 3271–3273.

(26) Synthesis of unsymmetrical staurosporinones: (a) Brüning, J.; Hache, T.; Winterfeldt, E. *Synthesis* **1994**, *1994*, 25–27. (b) Eils, S.; Winterfeldt, E. *Synthesis* **1999**, *1999*, 275–281. (c) Nomak, R.; Snyder, J. K. *Tetrahedron Lett.* **2001**, *42*, 7929–7933. (d) Trost, B. M.; Kirsche, M. J.; Berl, V.; Grenzer, E. M. *Org. Lett.* **2002**, *4*, 2005–2008.